The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.
Clew Medical aggregates data from multiple devices and information systems to identify and refine patterns that indicate patient deterioration.
